LDR Holding Corp. (NASDAQ:LDRH) shares fell 0% during trading on Friday . The company traded as low as $36.95 and last traded at $36.97, with a volume of 202,077 shares changing hands. The stock had previously closed at $36.98.

A number of research firms have recently commented on LDRH. Stephens downgraded LDR Holding Corp. from an “overweight” rating to an “equal weight” rating in a report on Wednesday, June 15th. Cowen and Company downgraded LDR Holding Corp. from an “outperform” rating to a “market perform” rating and raised their price target for the stock from $33.00 to $37.00 in a research note on Tuesday, June 14th. William Blair downgraded LDR Holding Corp. from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 7th. Barclays PLC downgraded LDR Holding Corp. from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $27.00 to $37.00 in a research note on Friday, June 10th. Finally, Royal Bank Of Canada downgraded LDR Holding Corp. from an “outperform” rating to a “sector perform” rating and raised their price target for the stock from $33.00 to $37.00 in a research note on Thursday, June 9th. Ten equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $37.73.

The company’s market capitalization is $1.08 billion. The company’s 50-day moving average is $32.04 and its 200-day moving average is $25.21.

LDR Holding Corp. (NASDAQ:LDRH) last released its quarterly earnings results on Tuesday, May 10th. The medical device company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.02. The business had revenue of $42.40 million for the quarter, compared to the consensus estimate of $42.90 million. LDR Holding Corp.’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period last year, the business earned ($0.12) EPS. On average, equities research analysts predict that LDR Holding Corp. will post ($0.82) EPS for the current fiscal year.

In related news, EVP Patrick Richard sold 25,000 shares of the stock in a transaction dated Friday, April 15th. The shares were sold at an average price of $27.60, for a total value of $690,000.00. Following the completion of the sale, the executive vice president now owns 528,463 shares in the company, valued at $14,585,578.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Several large investors recently added to or reduced their stakes in the stock. I.G. Investment Management LTD. bought a new stake in LDR Holding Corp. during the fourth quarter valued at $2,707,000. Napier Park Global Capital US LP bought a new stake in LDR Holding Corp. during the fourth quarter valued at $1,148,000. Wells Fargo & Company MN boosted its stake in LDR Holding Corp. by 41.0% in the fourth quarter. Wells Fargo & Company MN now owns 549,722 shares of the medical device company’s stock valued at $13,804,000 after buying an additional 159,748 shares during the last quarter. AWM Investment Company Inc. boosted its stake in LDR Holding Corp. by 270.6% in the fourth quarter. AWM Investment Company Inc. now owns 152,333 shares of the medical device company’s stock valued at $3,825,000 after buying an additional 111,233 shares during the last quarter. Finally, CAM Group Holding A S boosted its stake in LDR Holding Corp. by 42.8% in the fourth quarter. CAM Group Holding A S now owns 166,917 shares of the medical device company’s stock valued at $4,191,000 after buying an additional 50,000 shares during the last quarter.

LDR Holding Corporation is a global medical device company. The Company is focused on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms, both of which are designed for applications in the cervical and lumbar spine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.